Papers in refereed journals (JIF = Journal Impact Factor)
  1. Asymmetris Synthesis of Spirocyclic Pyrrolidines and Tetrahydrofurans by Chiral Aldol   Reactions and Phenylthio Migration.  K. Chibale and S. Warren*. Tetrahedron Lett., 1991, 32, 6645-6648. JIF=2.50
  2. Kinetic Resolutions in Anti Aldol Reactions with Racemic 2-Phenylthio      Aldehydes:  Asymmetric Synthesis of Cyclic Ethers and Lactones with Phenylthio Migration.K. Chibale and S. Warren*. Tetrahedron Lett., 1992, 33, 4369-4372.   JIF=2.50
  3. Kinetic Resolutions in Anti Aldol Reactions:  Asymmetric Synthesis of Heterocycles with Phenylthio Migration.  K. Chibale and S. Warren*. Phosphorus, Sulfur & Silicon, 1993, 74, 401-402.  JIF = 0.515
  4. The Stereochemically Controlled Synthesis of Spirocyclic Ethers and Lactones with Medium-Sized (7-, 8- and 12-Membered) Carbocyclic Rings by Phenylthio Migration:  1-Oxaspiro[4.n]alkanes and Alkan-2-ones with n = 6,7, and 11.  K. Chibale, R.C. Hartley, K.P. Jenkins, M. Simons, S. Warren* and I.C. Richards. Tetrahedron Lett., 1993, 34, 6783-6786.  JIF=2.50
  5. New Homochiral Binaphthol-Modified Organolanthanide Reagents for the Enantioselective Addition to Aldehydes.  K. Chibale, N. Greeves*, L. Lyford and E. J. Pease. Tetrahedron: Asymmetry 1993, 4, 2407-2410.   JIF = 2.53
  6. The Synthesis of Optically Active 2-Phenylthio Aldehydes.  K. Chibale and S. Warren*. Tetrahedron Lett., 1994, 35, 3991-3994.  JIF=2.50
  7. Asymmetric Aldol Reactions of Achiral 2-Phenylsulfanyl Aldehydes with Small   (5- and 6-Membered) and Medium-Sized (8- and 12-Membered) Carbocyclic Rings: The Synthesis of Homochiral Spirocyclic Lactones, Pyrrolidines and Tetrahydrofurans. K. Chibale and S. Warren*. J. Chem. Soc., Perkin Trans.1, 1995, 2411-2418.  JIF = 2.2
  8. Kinetic Resolution in Asymmetric Anti Aldol Reactions of Branched and Straight Chain Racemic 2-Phenylsulfanyl Aldehydes:  Asymmetric Synthesis of Cyclic Ethers and Lactones by         Phenylsulfanyl Migration.  K. Chibale and S. Warren*. J. Chem. Soc., Perkin Trans.1, 1996,         1935-1940.  JIF = 2.2
  9. Design, Synthesis and Biological Evaluation of Carbohydrate-Based Mimetics of cRGDFV. K.C. Nicolaou*, J.I. Trujillo and K. Chibale. Tetrahedron 1997, 53, 8751-8778.   JIF = 3.01
  10. Design, Synthesis and Biological Evaluation of Nonpeptide Integrin Antagonists.
    K.C. Nicolaou*, J.I. Trujillo, B. Jandeleit, K. Chibale, M. Rosenfeld, B. Diefenbach, D.A. Cheresh and S.L. Goodman. Bioorg. Med. Chem, 1998, 6, 1185-1208.   JIF = 3.04
  11. Synthesis and Evaluation of 9,9-Dimethylxanthene Tricyclics Against Trypanothione Reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani. K. Chibale*, M. Visser, V. Yardley, S.L. Croft and A.H. Fairlamb. Bioorg. Med. Chem, Letts 2000, 10, 1147-1150.   JIF = 2.59
  12. New Amine and Urea Analogs of Ferrochloroquine: Synthesis, Antimalarial Activity In Vitro and Electrochemical Studies. K. Chibale*, J.R. Moss, M. Blackie, D. van Schalkwyk and P.J. Smith. Tetrahedron Letts 2000, 41, 6231-6235.  JIF = 2.50
  13. Modulation of Human Mammary Cell Sensitivity to Paclitaxel by New Quinoline Sulfonamides.  K. Chibale*, I. Ojima, H. Haupt, X. Geng, P. Pera and R. J. Bernacki. Bioorg. Med. Chem. Letts. 2001, 11, 2457-2460.   JIF =2.59
  14. Antiprotozoal and Cytotoxicity Evaluation of Sulfonamide and Urea Analogs of Quinacrine.K. Chibale*, H. Haupt, H. Kendrick, V. Yardley, A. Saravanamuthu, A.H. Fairlamb and S.L. Croft. Bioorg. Med. Chem. Letts. 2001, 11, 2655-2657.  JIF =2.59
  15. A Novel and Efficient Regiospecific Preparation of Arenesulfonamide Derivatives of 3,5-Diamino-1,2,4-triazole.K. Chibale*, J. Dauvergne and P. J. Wyatt. Synthesis, 2002, 185- 190.  JIF = 2.4
  16. Convenient synthesis of disulfide substrates for trypanothione reductase using polymer-supported reagents.  K. Chibale*, A. Chipeleme and S. Warren.  Tetrahedron Lett., 2002, 43(8), 1587-1589.  JIF=2.50
  17. A Chemical Approach towards Understanding the Mechanism and Reversal of Drug Resistance in Plasmodium falciparum: Is it Viable? K. Chibale*. International Union of Biochemistry and Molecular Biology (IUBMB) Life, 2002, 53, 249-252.   JIF =2.91
  18. Synthesis and antimalarial activity in vitro of new ruthenocene-chloroquine analogues.  P. Beagley, M. A. L. Blackie, K. Chibale*, C. Clarkson, J. R. Moss* and P. J. Smith.  J. Chem. Soc., Dalton. Trans., 2002, 4426-4433.   JIF =3.93
  19. Towards broadspectrum antiparasitic agents, K. Chibale*, ARKIVOC, 2002, (ix), 93-98  JIF =1.21
  20. Design, synthesis, and evaluation of taxanes as potential antimalarial agents. J Chen, L Kuznetsova, K Chibale, I Ojima et al.  Abstracts of Papers of the American Chemical Society   2003, 226, U48-U48  JIF = 8.80
  21. Exploring the potential of xanthene derivatives as trypanothione reductase inhibitors and chloroquine potentiating agents.  K. Chibale*, M. R. Visser, D. van Schalkwyk, P. J. Smith, A. Saravanamuthu and A. H. Fairlamb. Tetrahedron, 2003, 59, 2289-2296.   JIF =3.04
  22. The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors. K. Chibale* and C. C. Musonda.  Curr. Med. Chem. 2003, 10, 1863-1889.   JIF =5.38
  23. Synthesis and Antiplasmodial Activity in vitro of New Ferrocene-chloroquine Analogues.  P. Beagley, M. A. L. Blackie, K. Chibale,* C. Clarkson, R. Meijboom, J. R. Moss,* P. J. Smithand H. Su. Dalton Transactions, 2003, 3046- 3051.   JIF =3.93
  24. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain.  I. Chiyanzu, E. Hansell, J. Gut, P. J. Rosenthal, J. H. McKerrow and K. Chibale*. Bioorg. Med. Chem. Letts. 2003. 13, 3527-3530.  JIF =2.59
  25. Synthesis and antimalarial activity in vitro of new heterobimetallic complexes:  Rh and Au derivatives of chloroquine and a series of ferrocenyl-4-amino-7chloroquinolines.  M. A. L. Blackie, P. Beagley, K. Chibale, C. Clarkson, A. T. Hutton, J. R. Moss* and P. J. Smith. J. Organomet. Chem. 2003, 688, 144-152.   JIF =2.53
  26. Synthesis of totarol amino alcohol derivatives and their antiplasmodial activity and cytotoxicity.  C. Clarkson, C. C. Musonda, K. Chibale*, W. E. Campbell and P. J. Smith.  Bioorg. Med. Chem, 2003, 11, 4417-4422.    JIF =3.04
  27. Unprecedented observation of sulfonamides in the transesterification of N-unsubstituted carbamates with sulfonly chlorides.  J. Dauvergne, K. Wellington and K. Chibale*. Tetrahedron Lett., 2004, 45, 43-47  JIF =2.50
  28. Application of combinatorial and parallel synthesis methodologies to antiparasite drug discovery, C. C. Musonda and K.Chibale*. Curr. Med. Chem. 2004, 11, 2519-2533.   JIF =5.38
  29. Synthesis and Structure Activity Relationships of Parasiticidal Thiosemicarbazone Cysteine Protease Inhibitors against P.falciparum, T. brucei and T. cruzi.  D. Greenbaum*, Z. Mackey, E. Hansell, P. Doyle, J. Gut, C. R. Caffrey, J. Lehman, P. J. Rosenthal, J. H. McKerrow, and K. Chibale*.  J. Med. Chem. 2004, 47, 3212-3219.   JIF =5.17
  30. Application of Multi-Component Reactions to Antimalarial Drug Discovery. Part 1.  Parallel Synthesis and Antiplasmodial Activity of New 4-Aminoquinoline Ugi Adducts. C. C. Musonda, D. Taylor, J. Lehman, J. Gut, P. J. Rosenthal and K. Chibale*. Bioorg. Med. Chem. Letts., 2004, 14, 3901-3905.  JIF =2.59
  31. The new permeability pathways: targets and selective routes for the development of new antimalarial agents. H. M. Staines*, J. C. Ellory and K. Chibale. Combinatorial Chemistry and High Throughput Screening  2005, 8, 81-88.   JIF =2.24
  32. Design, synthesis and antiplasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives.  I. Chiyanzu, C. Clarkson, P. J. Smith, J. Lehman, J. Gut. P. J. Rosenthal and K. Chibale*. Bioorg. Med. Chem., 2005, 13, 3249-3261.   JIF =3.04
  33. Exploiting a basic chemosensitizing pharmacophore hypothesis. Part 1: synthesis and biological evaluation of novel arylbromide and bicyclic chemosensitizers against drug-resistant malaria parasites F. Chouteau, D. Ramanitrahasimbola, P. Rasoanaivo* and K. Chibale*. Bioorg. Med. Chem. Letts., 2005, 15, 3024-3028.  JIF =2.59
  34. Reversal of chloroquine resistance in Plasmodium falciparum by 9H-xanthene derivatives. C.-P. Wu, D. A. van Schalkwyk, D. Taylor, P. J. Smith and K. Chibale*. International Journal of Antimicrobial Agents 2005, 26, 170-175   JIF =2.78
  35. Economic drug discovery and rational medicinal chemistry for tropical diseases. K. Chibale*. Pure & Applied Chemistry 2005, 77, 1957-1964.  JIF =2.75
  36. Arylpiperazines displaying preferential potency against chloroquine-resistant strains of the malaria parasite Plasmodium falciparum.  C.-A. Molyneaux, M. Krugliak, H. Ginsburg, and K. Chibale* Biochemical Pharmacology. 2005, 71, 61-68.  JIF =4.07
  37. Inhibitors of the trypanosome alternative oxidase reduce parasite growth in culture.  RD Ott, K Chibale, S Anderson, A Chipeleme, M Chaudhuri, N Colowick, and G C Hill.  Faseb J.   2006  20 A938-A938   JIF =7.09
  38. Novel Ketomethylene Inhibitors of Angiotensin-I Converting Enzyme (ACE): Inhibition and Molecular Modelling.  P. Redelinghuys, A. T. Nchinda, K. Chibale and E. D. Sturrock*. Biological Chemistry, 2006, 387, 461-466.   JIF =2.91
  39. Novel approaches to antimalarial drug discovery.  C. Biot*, and K. Chibale*. Infectious Disorders- Drug Targets-, 2006, 6, 173-204.  JIF = 4.82
  40. Application of Multi-Component Reactions to Antimalarial Drug Discovery. Part 2.  New Antiplasmodial and Antitrypanosomal 4- Aminoquinoline γ– and δ Lactams via a “Catch and Release” Protocol.  C. C. Musonda, J. Gut, P. J. Rosenthal V. Yardley, R. C. Carvalho de Souza and K. Chibale*. Bioorg. Med. Chem.  2006, 14, 5605-5615.   JIF =3.04
  41. Dual-Acting Diamine Antiplasmodial and Chloroquine Resistance Modulating Agents.  S. Yeh, P. J. Smith and K. Chibale*Biochemical Pharmacology 2006, 72, 156-165.   JIF =4.07
  42. Synthesis of Novel Keto-ACE Analogues as Domain-Selective Angiotensin-I Converting Enzyme Inhibitors A. T. Nchinda, K. Chibale, P. Redelinghuys, and E. D. Sturrock*. Bioorg. Med. Chem Lett.  2006, 16, 4612-4615.   JIF =2.59
  43. Synthesis and Molecular Modeling of a Lisinopril-Tryptophan Analogue Inhibitor of Angiotensin I-Converting Enzyme.  A. T. Nchinda, K. Chibale, P. Redelinghuys, and E. D. Sturrock*. Bioorg. Med. Chem Lett.  2006, 16, 4616-4619.  JIF =2.59
  44. Novel inhibitors of the trypanosome alternative oxidase inhibit Trypanosoma brucei brucei growth and respiration.  R. Ott, K. Chibale, S. Anderson, A. Chipeleme, M. Chaudhuri, A. Guerrah, N. Colowick, and G. C. Hill*.  Acta Tropica 2006, 100, 172-184.  JIF =2.44
  45. \Synthesis and Biological Evaluation of Phenolic Mannich Bases of Benzaldehyde and (thio) semicarbazone derivatives Against the Cystein Protease falcipain-2 and a chloroquine resistant strain of Plasmodium falciparum.  A. Chipeleme, J. Gut, P. J. Rosenthal and K.  Chibale*. Bioorg. Med. Chem.  2007, 15, 273-282.JIF = 3.04
  46. Purification of human malaria parasite hypoxanthine guanine xanthine phosphoribosyltransferase (HGXPRT) using immobilized Reactive Red 120.  B. Mbewe*, K. Chibale and D. B. McIntosh. Protein Expression and Purification 2007, 52, 153-158.   JIF =1.84
  47. Antiplasmodial hirsutinolides from Vernonia staehelinoides and their utilization towards a novel simplified pharmacophore.  P. Pillay*, R. Vleggaar, V. J. Maharaj, P. J. Smith, C. A. Lategan,. F. Chouteau and K. Chibale. Phytochemistry 2007, 68, 1200-1205.   JIF =3.19
  48. Application of Multicomponent Reactions to Antimalarial Drug Discovery. Part 3: Discovery of aminoxazole 4-aminoquinolines withpotentantiplasmodial activity in vitro.  C.C. Musonda, S. Little, V. Yardley and K. Chibale*. Bioorg. Med. Chem Lett.  2007, 17, 4733-4736.  JIF =2.59
  49. Metallocene-based antimalarials: An exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum.  M.A.L. Blackie, P. Beagley, S. L. Croft, H. Kendrick, J. R. Moss and K. Chibale*. Bioorg. Med. Chem.  2007, 15, 6510-6516.    JIF =3.04
  50. Synthesis of new 7-chloroquinolinyl thioureas and their biological investigation as potential anti-malarial and anticancer agents. A. Mahajan, S. Yeh, M. Nell, C E J van Rensburg and K. Chibale*. Bioorg. Med. Chem Lett.  2007, 17, 5683-5685.  JIF =2.59
  51. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. C. Biot,* B. Pradines, M-H. Sergeant, J. Gut, P. J. Rosenthal and K. Chibale. Bioorg. Med. Chem Lett.  2007, 17, 6434-6438   JIF =2.59
  52. Chemoselectivity and unusual internal acetal formation in the synthesis of a glycosidation precursor. A. T. Stevens, J. R. Bull and K. Chibale*.  Synlett  2007, 3175-3179.   JIF =2.61
  53. Effect of varying the anionic component of a copper (I) catalyst on homologation of arylacetylenes to allenes by the Mannich reaction. V. Kumar, A. Chipeleme and K. Chibale*. Eur. J. Org. Chem.  2008, 43-46.   JIF =3.07
  54. Studies in Iridoid Synthesis. Chemoselective Transformations of Cis-1,2,4,6-Tetrahydrophthalic Anhydride. A. T. Stevens, J. R. Bull and K. Chibale*. Org. Biomol. Chem., 2008, 6, 586-595.  JIF =3.76
  55. Meclonazepam Analogues as Potential New Antihelmintic Agents. A. Mahajan, V. Kumar, N. R. N. Mansour, Q. Bickle and K. Chibale*.Bioorg. Med. Chem Lett. 2008, 18, 2333-2336   JIF =2.59
  56. Metallocene Antimalarials: The Continuing Quest. M. A. L. Blackie and K. Chibale*. Metal-Based Drugs, 2008, 2008, 495123 doi:10.1155/2008/495123 JIF =Unknown
  57. Inhibition of Trypanothione Reductase and Glutathione Reductase by Ferrocenic 4-Aminoquinoline Ureas. M. A. L. Blackie, A. Saravanamuthu, A. H. Fairlamb and K. Chibale*. Arkivoc, 2008, (vi), 52-60   JIF =1.21
  58. Synthesis, antimalarial and cytotoxic evaluation of reversed chloroquines based on the 3,4-dihydropyrimidi-2(1H)-one scaffold. N. October, N. D. Watermeyer, V. Yardley, T. J. Egan, K. Ncokazi and K. Chibale*. ChemMedChem.  2008, 3, 1649-1653.   JIF =3.25
  59. Antiplasmodial, b-haematin inhibition, antitrypanosomal and cytotoxic activity in vitro of novel 4-aminoquinoline 2-imidazolines. C.C. Musonda, V.Yardley, R. C. Carvalho de Souza, K. Ncokazi, T. J. Egan and K. Chibale*.  Org. Biomol. Chem., 2008, 6, 4446 – 4451   JIF =3.76
  60. Synthetic Medicinal Chemistry of Antimalarial Natural Products. V. Kumar, A. Mahajan, and K. Chibale*. Bioorg. Med. Chem.  2009, 17, 2236-2275.JIF = 3.04 Paper ranked in the top ten of the most popular/most cited articles for 2009-2010 academic year in this journal
  61. Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. M. Hohman, K. Gregory, K. Chibale, P.J. Smith, S. Ekins and B. Bunin*. Drug Discovery Today, 2009,14, 261-70.   JIF =7.37
  62. Synthesis of novel anti-2-alkoxy-3-amino-3-arylpropan-1-ols and cis-5-alkoxy-4aryl-1,3-oxazinanes with antimalarial activity. M. D’hooghe, P. J. Smith, S. Dekeukeleire, K. Mollet, K. Chibale and N. De Kimpe* J. Med. Chem.  2009, 52, 4058-4062.   JIF =5.17
  63. Cycloaddition and One-Carbon Homologation Studies in the Synthesis of Advanced Iridoid Precursors. A. T. Stevens, M. R. Caira, J. R. Bull, and K. Chibale*Org. Biomol. Chem., 2009, 7, 3527- 3536.   JIF =3.76
  64. Pharmacologically relevant bifunctional compounds containing chloroquinoline and dihydropyrimidone moieties; syntheses and crystal structures of a target molecule and selected intermediates. N. D. Watermeyer, K. Chibale* and M.R. Caira*.  J. Chem. Crystallography. 2009, 39, (10), 753-760   JIF =0.63
  65. A New and Simple Synthesis of Sulfonyl Ureas from Sulfonamides and N-Alkyl-1,2,4-dithiazolidine-3,5-diones. R.K. Gessner and K. Chibale*.  Synlett. 2009, 17, 2839-2843    JIF =2.61
  66. Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo. M.A.L. Blackie, V. Yardley, and  K. Chibale*. Bioorg. Med. Chem. Lett. 2010, 20, 1078-1080.  JIF =2.59
  67. Synthesis, Antimalarial and Antitubercular Activity of Acetylenic Chalcones. R.H. Hans; E.M Guantai.; C. Lategan; P.J Smith,; B. Wan.; S.G Franzblau.; J. Gut; P. J Rosenthal, and  K. Chibale*. Bioorg. Med. Chem. Lett. 2010, 20, 942-944.   JIF =2.59
  68. Gold (I) Derived Thiosemicarbazone Complexes with rare halogen-halogen interaction-Reduction of \n[Au(damp-C1,N)Cl2], S. Khanye; N. B. Bathori, G. S. Smith, and  K. Chibale*. Dalton Transactions, 2010, 39 (10), 2697 – 2700.     JIF =3.93
  69. Comparison of the Antiplasmodial and Falcipain-2 Inhibitory Activity of β-Amino Alcohol Thiolactone-Chalcone and Isatin-Chalcone Hybrids. R.H. Hans, J. Gut, P.J. Rosenthal, and K. Chibale* Bioorg. Med. Chem. Lett. 2010, 20, 2234-2237.  JIF =2.59
  70. \Chloroquine resistance: proposed mechanisms and countermeasures. E. M. Guantai and K. Chibale*.  Current Drug Delivery. 2010, 7, 312-323 JIF = 1.5
  71. CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in antimalarial drug discovery initiatives. I. C Boulton*, S. Nwaka, I. Bathurst, M. Lanzer, D. Taramelli, H. Vial, C. Doerig, S. M. N. Efange, K. Chibale & S.A. Ward* Malaria Journal. 2010, 9, 202JIF =3.15
  72. Thiosemicarbazone Salicylaldiminato Palladium(II)-Catalyzed Mizoroki-Heck Reactions. G. Xie, P. Chellan, J. Mao*, K. Chibale, G. S. Smith* Advanced Synthesis & Catalysis 2010, 352, 1641-1647. JIF =5.47
  73. Synthesis, structures and in vitro biological screening of palladium(II) complexes of functionalised salicylaldimine thiosemicarbazones as antimalarial and anticancer agents.  P. Chellan, N. Shunmoogam-Gounden, D.T. Hendricks, J.Gut, P. J. Rosenthal, C. Lategan, P. J. Smith, K. Chibale, G.S. Smith*.  Eur.J. Inorg. Chem.  2010, 3520-3528.   JIF =3.10
  74. Cyclopalladated Complexes Containing Tridentate Thiosemicarbazone Ligands of Biological Significance: Synthesis, Structure and Antimalarial activity.  P. Chellan, S. Nasser, K. Chibale, G. S. Smith*.  Journal of Organometallic Chemistry.  2010, 695, 2225-2232.   JIF =2.53
  75. Synthesis and in vitro evaluation of gold(I) thiosemicarbazone complexes for antimalarial activity.  S.D. Khanye, G. Smith, J. Gut, P. J. Rosenthal and K. Chibale*.  Journal of Inorganic Biochemistry  2010, 104, 1079-1083.  JIF =3.71
  76. Novel Tetracyclic Structures from the Synthesis of Thiolactone-Isatin Hybrids.  R. H. Hans, H. Su and K. Chibale*.  Belstein Journal of Organic Chemistry  2010, 6,(78), 1-7 ( doi: 10.3762/bjoc.6.78) JIF=1.26
  77. Design, synthesis and in vitro antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds.  E. M. Guantai, K. Ncokazi a, T. J. Egan, J. Gut, P. J. Rosenthal, P. J. Smith, and K. Chibale*.  Bioorg. Med. Chem. 2010, 18, 8243-8256.  JIF =3.04
  78. Synthesis of 2-(aminomethyl)aziridines and their microwave-assisted ring opening to 1,2,3-triaminopropanes as novel antimalarial pharmacophores. M. D’hooghe,*, S. Kenis, K. Vervisch, C. Lategan , P. J. Smith, K. Chibale, N. De Kimpe* Eur. J. Med. Chem.  2011, 46, 579-587 JIF =3.36
  79. Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents. R.H. Hans, I. J. F. Wiid, P. D. Van Helden, B. Wan, S.G. Franzblau, J. Gut, P.J. Rosenthal, and K. Chibale* Bioorg. Med. Chem. Lett. 2011, 21, 2055-2058. JIF =2.59
  80. How can natural products serve as a viable source of lead compounds for the development of new/novel antimalarials? E. M. Guantai and K. Chibale* Malaria Journal 2011, 10(Suppl 1):S2 (15 March 2011). JIF =3.15
  81. Extracting molecular information from African natural products to facilitate unique African-led drug discovery efforts. E. M. Guantai. C. M. Masimirembwa, and K. Chibale* Future Medicinal Chemistry. 2011,3(3) 257-261 JIF = 10
  82. Facile transformation of Biginelli pyrimidin-2(1H)-ones to pyrimidines. In vitro evaluation as inhibitors of Mycobacterium tuberculosis and modulators ofcytostatic activity. K. Singh, K. Singh, B. Wan, S. Franzblau, K. Chibaleand J. Balzarini Eur. J. Med. Chem.  2011, 46, 2290-2294.  JIF =3.36
  83. The state of the art in anti-malarial drug discovery and development.  J. Burrows*, K. Chibale and T.N.C. Wells.  Current Topics in Medicinal Chemistry 2011, 11 (10), 1226-1254. JIF =4.31
  84. Antiplasmodial and antitumour activity of artemisinin analogs derived via the aza-Michael addition reaction. T.-S Feng; E. M. Guantai, M. J. Nell; C.E.J van Rensburg; H. C. Hoppe, and K. Chibale* Bioorg. Med. Chem. Lett. 2011, 21, 2882-2886. JIF =2.59
  85. Synthesis and in vitro antitubercular activity of ferrocene-based hydrazones.  A. Mahajan, L. Kremer, S. Louw, Y. Guéradel, K. Chibale, and C. Biot Bioorg. Med. Chem. Lett.  2011, 21, 10, 2866-2868 JIF =2.59
  86. Linear free energy relationships predict coordination and π-stacking interactions of small molecules with ferriprotoporphyrin IX.  D. Kuter, K. Chibale, and T. J. Egan*.  Journal of Inorganic Biochemistry  2011, 105, 684-692.  JIF =3.71
  87. Molecular Structure of an Unexpected Binuclear Salicylaldimine Semicarbazone Palladium(II) Complex. P. Chellan, K. Chibale and G. S. Smith*.  J Chem Crystallography, 2011, 41, 747-750 JIF = 0.67
  88. Enone- and chalcone-chloroquinoline hybrid analogs: In silico-guided design, synthesis, antiplasmodial activity, in vitro metabolism and mechanistic studies. E. M. Guantai, K. Ncokazi, T. J. Egan, J. Gut, P. J. Rosenthal, R. Bhampidipati, A. Kopinathan, P. J. Smith and K. Chibale*  J. Med. Chem.  2011, 54, 3637–3649.   JIF =5.17
  89. Effects of highly active novel artemisinin-chloroquinoline hybrid compounds on beta-hematin formation, parasite morphology and endocytosis in Plasmodium falciparum. T.-S Feng, E.M. Guantai, M. Nell, C.E.J van Rensburg, K. Ncokazi, T. J. Egan, H. C. Hoppe* and K. Chibale*Biochemical Pharmacology 2011, 77, 156-165. JIF = 4.07
  90. Antimalarial Pyrido[1,2-a]benzimidazoles. A.J. Ndakala, R.K. Gessner, P.W. Gitari, N. October, K.L. White, A. Hudson, F. Fakorede, D.M. Shackleford,  M. Kaiser, C. Yeates, S.A. Charman, and K. Chibale*  J. Med. Chem.  2011, 54, in press, accepted for publication.   JIF =5.17
  91. Antiplasmodial and Cytotoxicity Evaluation of 3-functionalized 2-Azetidinone derivatives. P. Singh, S. Sachdeva, R. Raj, Vipan Kumar,* M.P. Mahajan, S. Nasser, L. Vivas, J. Gut, P.J. Rosenthal, T.-S. Feng, and  K. Chibale Bioorg. Med. Chem. Lett. 2011, 21, In Press, Accepted for publication. JIF =2.59
  92. Drug repositioning in the treatment of malaria and tuberculosis. A. Nzila*, Z. Ma, and K. Chibale Future Medicinal Chemistry. 2011,3(3) In press, accepted for publication JIF = 10